

What Makes the PSG Unique?

The PSG has carried out cooperative therapeutic research since 1986, beginning with the NIH-sponsored DATATOP (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism) clinical trial. Since then we have carried out more than 35 multi-center trials examining the symptomatic and neuroprotective effects of experimental interventions in Parkinson disease. The PSG has partnered with numerous pharmaceutical companies and the National Institutes of Health (NIH) in bringing new drugs for Parkinson disease to the market including pramipexole, entacapone, rotigotine and rasagiline.

Since our inception, we have actively published all of our research efforts in internationally recognized peer-reviewed journals in an effort to make all of our research progress in PD and related disorders available to the public. Our publication list currently includes over 200 abstracts and journal articles.

PSG Physicians (Investigators) and Other Health Care Providers (Coordinators) Network

The core resource of the PSG is a network of experienced investigators, coordinators and consultants from academic/research institutions in the United States, Canada and Puerto Rico. Membership in the PSG is based on active participation in PSG clinical trials or through active participation on committees or working groups of the PSG. The PSG now includes more than 400 active investigators, coordinators and scientists from approximately 135 PSG sites located throughout the United States, Canada and Puerto Rico. Research is conducted at all of these sites in an effort to find new treatments (e.g., medications, surgical procedures) for PD, as well as new ways to diagnose PD and related neurological disorders. Site investigators and coordinators are selected for participation in PSG trials on the basis of their experience and performance in conducting clinical research studies in Parkinson disease.

The PSG is governed by a Constitution and Bylaws and an elected Executive Committee that is primarily responsible for the direction and oversight of its research projects and activities.

The PSG Executive Committee oversees all the PSG study steering committees, the Scientific Review Committee, the Mentoring Committee, the Nominating Committee, the Credentials Committee, the Publications Committee, the Standards Committee, the Study Budget Committee, and the Symposia Committee (please see the PSG Standing Committee Members list). The Executive Committee is also responsible for overseeing the PSG working groups (Cognitive/Psychiatric (Behavior), Biomarkers, Genetics and Environmental Risk, Other Non-Motor Features of PD, Functional Neurosurgical and Classic Motor) that are responsible for developing new PSG projects. PSG members interested in joining a working group may contact the Chair of that group.